Small
cap stocks making big moves on Friday, September 26, 2014 (as of 4 pm EST), as
reported by Sean Mason, SmallCapPower.com
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)
shares shot up 19% to $63.76 on volume of more than 3.9 million shares Friday
after the biopharma firm reported that clinical data from a Phase 1 study of
AG-120, an orally available, selective, potent inhibitor of the mutated IDH1
protein, will be highlighted in a late breaking oral presentation at the 26th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking
place in November.
As well,
shares of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
slid 20% to $5.41 on more than 3.8 million shares traded as the specialty
pharmaceutical company said it would take longer than expected to resubmit its New
Drug Application for Zalviso, which is designed to improve the management of
moderate-to-severe acute pain in adult patients in a hospital setting, to the U.S.
Food and Drug Administration (FDA).
Digital Ally, Inc. (NASDAQ: DGLY),
meanwhile, announced that it has received an order from a U.S. military base
involving the company’s complete video evidence gathering system. Digital Ally
stock popped 17% to $17.63 following the announcement.
Finally,
Repros Therapeutics Inc. (NASDAQ: RPRX)
shares climbed 17% to $10.48 after the developer of small molecule drugs reported
what it called top line results from the second of two identical pivotal
studies comparing Androxal to a leading FDA approved topical gel (Androgel
1.62) and placebo.
